J.W. Cole Advisors Inc. Raises Position in Cencora, Inc. (NYSE:COR)

J.W. Cole Advisors Inc. grew its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 49.3% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 6,018 shares of the company's stock after buying an additional 1,987 shares during the quarter. J.W. Cole Advisors Inc.'s holdings in Cencora were worth $1,674,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Cornerstone Planning Group LLC lifted its holdings in Cencora by 106.7% in the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock valued at $26,000 after buying an additional 48 shares during the period. Hoey Investments Inc. acquired a new position in shares of Cencora during the first quarter valued at about $28,000. Banque Transatlantique SA acquired a new position in shares of Cencora during the fourth quarter valued at about $29,000. Vermillion Wealth Management Inc. acquired a new position in shares of Cencora during the fourth quarter valued at about $38,000. Finally, Golden State Wealth Management LLC raised its holdings in shares of Cencora by 157.6% during the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after purchasing an additional 104 shares during the period. Institutional investors own 97.52% of the company's stock.

Insider Transactions at Cencora

In other news, CEO Robert P. Mauch sold 4,968 shares of Cencora stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the sale, the chief executive officer owned 42,351 shares of the company's stock, valued at approximately $12,455,852.61. The trade was a 10.50% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of Cencora stock in a transaction dated Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total transaction of $4,266,543.26. Following the sale, the chairman directly owned 309,913 shares in the company, valued at $90,702,237.71. The trade was a 4.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock worth $9,993,789 in the last ninety days. Insiders own 10.80% of the company's stock.

Cencora Trading Down 0.1%

Shares of COR stock traded down $0.28 on Friday, hitting $290.17. 785,267 shares of the company's stock traded hands, compared to its average volume of 1,072,635. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The company's fifty day simple moving average is $293.31 and its 200 day simple moving average is $274.53. The stock has a market capitalization of $56.24 billion, a price-to-earnings ratio of 33.66, a P/E/G ratio of 1.44 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. The firm had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The company's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.80 EPS. Equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date was Friday, May 16th. Cencora's payout ratio is 25.52%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on COR shares. Bank of America upped their target price on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a report on Friday, April 11th. UBS Group upped their price objective on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Jefferies Financial Group upped their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a research report on Monday, June 30th. Citigroup increased their target price on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Finally, Robert W. Baird increased their target price on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $309.83.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.